Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.48 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169595 | 0.92 | SLC5A2 (0.52) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL10169611 | 0.87 | SLC5A2 (0.50) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12407966 | 0.87 | SLC5A2 (0.48) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL499649 | 0.84 | SLC5A2 (0.45) | SLC5A2SLC5A1 | |
| SCHEMBL10169597 | 0.84 | SLC5A2 (0.46) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL10169609 | 0.84 | SLC5A2 (0.47) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL15627069 | 0.84 | SLC5A2 (0.42) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL15627071 | 0.84 | SLC5A2 (0.44) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2600120 | 0.84 | SLC5A2 (0.44) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14850074 | 0.84 | SLC5A2 (0.42) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802637-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140031300-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575321-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120329732-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8106021-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110207661-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207661-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1525/4885 |
| US-20120329732-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1525/4885 |
| US-20140031300-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.